HistoSonics, the maker of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the closing of an oversubscribed $102 million Series D financing round.
The round was led by Alpha Wave Ventures, a global growth-stage investment firm, with participation from new investors Amzak Health and HealthQuest Capital, and existing investors Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Venture Investors, Lumira Ventures, Yonjin Venture, the State of Wisconsin Investment Board, and others.
Histotripsy is a novel form of focused ultrasound that uses high-frequency, very short pulses to create a "cloud of bubbles" intended to mechanically destroy and liquefy targeted liver tumors. These clouds of bubbles form and collapse in microseconds, generating mechanical forces strong enough to destroy tissue at the cellular and subcellular level in a non-invasive and non-thermal manner. Histotripsy offers a promising alternative to treatments such as surgery, radiation, and chemotherapy, which often have significant side effects.
